This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
by Zacks Equity Research
LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
by Zacks Equity Research
ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
by Zacks Equity Research
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
by Zacks Equity Research
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
by Zacks Equity Research
Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
by Zacks Equity Research
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
by Zacks Equity Research
Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.
Wall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
by Zacks Equity Research
Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
by Zacks Equity Research
Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.
Wall Street Analysts Believe Xenon Pharmaceuticals (XENE) Could Rally 36.75%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -4.35% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 6.90% and 86.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences (GILD) Q2 Earnings Lag Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -1.61% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.